^
Association details:
| Biomarker: | HER-2 S310F |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | tuxobertinib (BDTX-189) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of BDTX-189 in Patients with Advanced Solid Malignancies
Excerpt:
...Eligible mutations are summarized in Appendix I. Eligible patients will be assigned to one of the 4 following cohorts:Cohort 1: NSCLC with EGFR or HER2 exon 20 insertion mutationCohort 2: Breast cancer with an allosteric HER2 mutation and EGFR/HER2 exon 20 insertion mutationsCohort 3: Any tumor (except breast) with an S310F/Y mutationCohort 4: Any other allosteric HER2 mutation and EGFR/HER2 exon 20 insertion mutations not assigned to Cohorts 1-3;Adequate archival tumor tissue or willing to undergo pretreatment biopsy;Measurable disease according to RECIST version 1.1....
Trial ID:
Title:
Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium
Published date:
10/26/2020
Excerpt:
Additionally, BDTX-189 demonstrated dose-dependent tumor inhibition and regression in both engineered HER2 S310F tumor models and in EGFR Exon 20 insertion PDX models.
